InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Bolt Biotherapeutics, Inc.

BOLT Clue Score55
United States Fiscal year ends December CIK 0001641281
$4.11 +12.60% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $4.11 −68.38% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 5 Feb 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Revenue0.2Operating income−49.2Net income−60.7Fiscal year 2021Revenue1.3 +445.5%Operating income−92.8Net income−98.6EPS, diluted−2.97Fiscal year 2022Revenue5.7 +354.7%Operating income−90.3Net income−88.1EPS, diluted−2.36Fiscal year 2023Revenue7.9 +37.5%Operating income−76.2Net income−69.2EPS, diluted−1.83Fiscal year 2024Revenue7.7 −2.4%Operating income−73.0Net income−63.1EPS, diluted−33.06Fiscal year 2025Revenue7.7 +0.1%Operating income−36.1Net income−33.4EPS, diluted−17.85
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.2 1.3 5.7 7.9 7.7 7.7
Growth +445.5% +354.7% +37.5% −2.4% +0.1%
Operating income −49.2 −92.8 −90.3 −76.2 −73.0 −36.1
Net income −60.7 −98.6 −88.1 −69.2 −63.1 −33.4
Growth
EPS, diluted n/a −2.97 −2.36 −1.83 −33.06 −17.85

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Operating margin−21,290.9%Net margin−26,289.2%Free cash flow margin−21,891.8%Fiscal year 2021Operating margin−7,364.1%Net margin−7,824.7%Free cash flow margin−4,714.6%Fiscal year 2022Operating margin−1,576.6%Net margin−1,537.8%Free cash flow margin−1,369.5%Fiscal year 2023Operating margin−967.4%Net margin−878.6%Free cash flow margin−885.4%Fiscal year 2024Operating margin−949.9%Net margin−820.8%Free cash flow margin−797.5%Fiscal year 2025Operating margin−469.3%Net margin−433.7%Free cash flow margin−518.8%
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −21,290.9% −7,364.1% −1,576.6% −967.4% −949.9% −469.3%
Net margin −26,289.2% −7,824.7% −1,537.8% −878.6% −820.8% −433.7%
Free cash flow margin −21,891.8% −4,714.6% −1,369.5% −885.4% −797.5% −518.8%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−47.3Capital expenditure−3.3Free cash flow−50.6Fiscal year 2021Operating cash flow−57.1Capital expenditure−2.3Free cash flow−59.4Fiscal year 2022Operating cash flow−76.5Capital expenditure−2.0Free cash flow−78.5Fiscal year 2023Operating cash flow−69.5Capital expenditure−0.2Free cash flow−69.7Fiscal year 2024Operating cash flow−61.3Capital expenditure−0.0Free cash flow−61.3Fiscal year 2025Operating cash flow−39.9Capital expenditure−0.1Free cash flow−39.9
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −47.3 −57.1 −76.5 −69.5 −61.3 −39.9
Capital expenditure −3.3 −2.3 −2.0 −0.2 −0.0 −0.1
Free cash flow −50.6 −59.4 −78.5 −69.7 −61.3 −39.9
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash5.5Shareholders’ equity−104.9Fiscal year 2021Cash27.4Shareholders’ equity250.1Fiscal year 2022Cash9.2Shareholders’ equity171.5Fiscal year 2023Cash10.8Shareholders’ equity112.7Fiscal year 2024Cash7.2Shareholders’ equity57.2Fiscal year 2025Cash11.7Shareholders’ equity26.5
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 5.5 27.4 9.2 10.8 7.2 11.7
Shareholders’ equity −104.9 250.1 171.5 112.7 57.2 26.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.2 1.3 5.7 7.9 7.7 7.7
Growth +445.5% +354.7% +37.5% −2.4% +0.1%
40.4 75.7 73.1 61.5 57.5 28.5
9.1 18.4 22.9 22.5 18.5 13.8
−49.2 −92.8 −90.3 −76.2 −73.0 −36.1
Growth
n/a n/a n/a n/a −63.1 −33.4
0.0 0.0 0.0 0.0 0.0 0.0
−60.7 −98.6 −88.1 −69.2 −63.1 −33.4
Growth
Per share
n/a −2.97 −2.36 −1.83 −33.06 −17.85
n/a −2.97 −2.36 −1.83 −33.06 −17.85
Growth
2.0 33.2 37.4 37.8 1.9 1.9
n/a 33.2 37.4 37.8 1.9 1.9
Growth +12.5% +1.2% −95.0% −2.1%

† The diluted share count jumps at 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 101.6% a year over five years.
  • Operating margin is up 20,821.6 points on five years ago, at -469.3%.
  • A net loss in 6 of 6 years on file.